List of Bunavail drug patents

Bunavail is owned by Bdsi.

Bunavail contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.

Bunavail has a total of 4 drug patents out of which 0 drug patents have expired.

Bunavail was authorised for market use on 06 June, 2014.

Bunavail is available in film;buccal dosage forms.

Bunavail can be used as treatment of opioid dependence, maintenance treatment of opioid dependence.

The generics of Bunavail are possible to be released after 24 April, 2035.

BUNAVAIL Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device
Apr, 2035

(12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

BUNAVAIL family patents

40

United States

8

Japan

6

Australia

5

China

5

European Union

4

Brazil

4

Canada

3

Russia

3

New Zealand

3

Norway

3

Korea, Republic of

3

Hong Kong

3

Israel

2

Singapore

2

Spain

2

Mexico

2

EA

1

Croatia

1

South Africa

1

Cyprus

1

Slovenia

1

Hungary

1

Ukraine

1

Poland

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic